[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100577915":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":21,"responsibleParty":40,"collaborators":45,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":61,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":70,"overallStatus":24,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Tampere Heart Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Patients with Coronary Artery Disease",null,"The study will recruit adult patients diagnosed with coronary artery disease (CAD) who are living in the Wellbeing Services County of Pirkanmaa. CAD must be with an invasive coronary angiogram or computed tomography angiogram (CTA), which cardiologists evaluate based on current guidelines for stenosis level evaluation and fractional flow reserve (FFR) results. An invasive coronary angiogram or CTA must be done within three (3) months before recruitment. The study subjects must have a good or moderate everyday functional ability.\n\nThe study is non-interventional.",[13,18],{"name":14,"role":15,"phone":10,"phoneExt":16,"email":17},"Jussi Hernesniemi, Professor","CONTACT","+358 3 311 611","jussi.hernesniemi@tuni.fi",{"name":19,"role":15,"phone":16,"phoneExt":10,"email":20},"Juho Tynkkynen, Medical Doctor, Phd","juho.tynkkynen@pirha.fi",[22],{"facility":23,"status":24,"city":25,"state":26,"zip":27,"country":28,"countryCode":29,"cosmosGeoPoint":30,"geoPoint":35,"contacts":36},"Tampere University Hospital Tampere Heart Centre","RECRUITING","Tampere","Pirkanmaa","33100","Finland","FI",{"type":31,"coordinates":32},"Point",[33,34],23.78712,61.49911,{"lat":34,"lon":33},[37],{"name":38,"role":15,"phone":16,"phoneExt":10,"email":39},"Kati Helleharju, Research cordinator","kati.helleharju@sydansairaala.fi",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":44,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jussi Hernesniemi","Research Director","Tampere University Hospital",[46,48],{"name":47,"class":6},"Tampere University",{"name":44,"class":6},"100577915","tampere-coronary-artery-disease-and-sudden-cardiac-arrest-study-100577915",false,"NCT06804499","Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study","CADSCA","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. A patient who lives in the area of 'Wellbeing Services County of Pirkanmaa' and seeks treatment for coronary artery disease (CAD).\n3. CAD is diagnosed with invasive coronary angiogram or computed tomography angiogram (CTA) which is evaluated by cardiologists based on current guidelines for stenosis level evaluation and fractional flow reserve (FFR) results.\n4. An invasive coronary angiogram or CTA is done within three (3) months.\n5. Good or moderate everyday functional ability\n\nExclusion Criteria:\n\n1. Life expectancy \\\u003C1 months.\n2. A significant valvular heart disease treated previously (endovascular or surgical) or requires treatment (endovascular or surgical) in the next three (3) months.\n3. Previously implanted cardioverter-defibrillators (ICD) or will be implanted in the next three (3) months.\n4. An active malignancy (ongoing treatment for a solid tumour, metastatic solid tumour, fast progressing haematological malignancy, or equal malignant disease).\n5. A significant neurodegenerative disease (dementia, Mini-Mental State Examination (MMSE) \\\u003C23 or equivalenneurodegenerative disease affecting everyday functional ability, like ALS, myositis, prograded MS-disease or Parkinson's disease).\n6. Intellectual disability or a significant disability affecting cognitive functions\n7. Do-not-resuscitate (DNR) treatment decision\n\nSubgroup with blood samples:\n\nBlood samples are withdrawn from all study subjects under 76 years of age. Additionally, PaxGene samples are withdrawn from i) all study subjects under 65 years of age and ii) subjects between 65-76 years, if they have detected QRS-time\\>110ms in the latest ECG.","ALL","18 Years",{"count":59,"type":60},4000,"ESTIMATED","15 Years","OBSERVATIONAL","The goal of this observational study is to recognize clinical and genetic risk factors for sudden cardiac arrest (SCA) and death (SCD) in patients with coronary artery disease (CAD).\n\nThe main questions it aims to answer are:\n\nAre we able to recognize clinical or treatment-related risk factors for SCA or SCD? Can we identify new genetic risk factors for SCA or SCD in patients under 75 years?\n\nParticipants diagnosed with CAD answer a short survey about their medical history and socioeconomic status. A standard ECG addition to a five (5) minute ECG recording is taken from all the study subjects. In addition to a few short physiological tests (e.g. blood pressure, height, weight, grip strength), a blood sample is withdrawn from a selected group of study subjects.\n\nMedical healthcare records are used to follow all study subjects, and no follow-up visits are required.",[65,66,67,68,69],"Sudden Cardiac Arrest","Sudden Cardiac Death","Sudden Cardiac Death Due to Cardiac Arrhythmia","Coronary Arterial Disease (CAD)","Acute Coronary Event",[71,72,73,74],"sudden cardiac death","sudden cardiac arrest","coronary artery disease","acute coronary syndrome","2025-01-27",{"date":77,"type":78},"2025-02-03","ACTUAL",{"date":80,"type":78},"2025-01-13",{"date":82,"type":60},"2042-12-31",{"name":5,"class":6},1]